CymaBay Therapeutics ROE 2013-2019 | CBAY

Current and historical return on equity (ROE) values for CymaBay Therapeutics (CBAY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. CymaBay Therapeutics ROE for the three months ending June 30, 2019 was -39.95%.
CymaBay Therapeutics ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2019-06-30 $-0.09B $0.24B -39.91%
2019-03-31 $-0.08B $0.26B -38.77%
2018-12-31 $-0.07B $0.17B -37.97%
2018-09-30 $-0.06B $0.19B -34.50%
2018-06-30 $-0.05B $0.20B -32.93%
2018-03-31 $-0.04B $0.21B -40.41%
2017-12-31 $-0.03B $0.09B -59.02%
2017-09-30 $-0.03B $0.09B -113.73%
2017-06-30 $-0.03B $0.00B -432.00%
2017-03-31 $-0.03B $0.01B -263.16%
2016-12-31 $-0.03B $0.00B -211.76%
2016-09-30 $-0.03B $0.01B -138.67%
2016-06-30 $-0.03B $0.02B -106.12%
2016-03-31 $-0.02B $0.02B -79.21%
2015-12-31 $-0.02B $0.03B -61.86%
2015-09-30 $-0.02B $0.03B -106.02%
2015-06-30 $-0.02B $0.02B -115.79%
2015-03-31 $-0.02B $0.02B -145.45%
2014-12-31 $-0.03B $0.01B -216.95%
2014-09-30 $0.19B $0.03B 1206.25%
2014-06-30 $0.24B $0.01B 1668.97%
2014-03-31 $0.24B $0.01B 1920.00%
2013-12-31 $0.24B $0.02B 2502.56%
2013-06-30 $-0.02B $0.00B inf%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.383B $0.010B
CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $54.365B 9.92
Mylan (MYL) United Kingdom $10.833B 4.77
Teva Pharmaceutical Industries (TEVA) Israel $8.222B 3.23
Bausch Health Cos (BHC) Canada $8.146B 5.43
Dr Reddy's Laboratories (RDY) India $6.299B 21.24
ASPEN PHARMACR (APNHY) South Africa $2.850B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.520B 14.86
Amphastar Pharmaceuticals (AMPH) United States $0.990B 48.77
Homology Medicines (FIXX) United States $0.897B 0.00
Voyager Therapeutics (VYGR) United States $0.672B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.462B 0.00
Akorn (AKRX) United States $0.462B 0.00
Assembly Biosciences (ASMB) United States $0.373B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.205B 0.28
Zynerba Pharmaceuticals (ZYNE) United States $0.196B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.187B 0.00
Sol-Gel Technologies (SLGL) Israel $0.168B 0.00
Teligent (TLGT) United States $0.052B 0.00
China Pharma Holdings (CPHI) China $0.011B 0.00